Nimotuzumab plus beeldgeleide radiotherapy for elderly patiënten met locally advanced cervical squamous cell carcinoma: Interim analyse of a prospectieve multi-center phase Ⅱ trial

Elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC) generally have fewer therapeutic choices. Nimotuzumab, as an epidermal growth factor receptor (EGFR)-targeted humanized monoclonal antibody, has low toxicity, and shown antitumor efficacy in cervical cancer in preliminary study. So we wanted to explore efficacy and safety of nimotuzumab and image-guided radiotherapy for elderly patients with LACSCC.